fairplus stamp

ABIRISK

Description

Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk

Accession number

dc9b062e-147a-11eb-b51f-8c8590c45a21

Project acronym

ABIRISK

Project website

http://www.abirisk.eu

Start date

2012-03-01

End date

2018-02-28

Funding

IMI1 - Call 3 (Grant number 115303)

Types

IMI projects

Project publications

http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0162752 https://pubmed.ncbi.nlm.nih.gov/25959571 https://pubmed.ncbi.nlm.nih.gov/33125391 https://pubmed.ncbi.nlm.nih.gov/30447419 https://pubmed.ncbi.nlm.nih.gov/31194850 https://pubmed.ncbi.nlm.nih.gov/30420245 https://pubmed.ncbi.nlm.nih.gov/29875313

Keywords

IMI projects Translational Medicine Biologicals Tools for predicting/monitoring efficacy Manufacturing technologies

Accession number	Title	Create date	Study	hosted at UL
6bd9243b-0368-4cc9-bc92-d00ba1d40b75	Genotyping of ABIRISK cohorts	2016-04-01	-	No
Show deprecated records

Title	Primary purpose	Study type	Organism
ABI-MS	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment	observational	Homo sapiens
ABI-RA	Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients (ABI-RA)	observational	Homo sapiens
ABI-IBD	Anti-Biopharmaceutical Immunization : Prediction and analysis of clinical relevance to minimize the risk in Inflammatory bowel disease (IBD)	observational	Homo sapiens